MX2009011165A - Formulaciones farmaceuticas que contienen derivados del acido lipoico. - Google Patents

Formulaciones farmaceuticas que contienen derivados del acido lipoico.

Info

Publication number
MX2009011165A
MX2009011165A MX2009011165A MX2009011165A MX2009011165A MX 2009011165 A MX2009011165 A MX 2009011165A MX 2009011165 A MX2009011165 A MX 2009011165A MX 2009011165 A MX2009011165 A MX 2009011165A MX 2009011165 A MX2009011165 A MX 2009011165A
Authority
MX
Mexico
Prior art keywords
acid derivatives
pharmaceutical formulations
formulations containing
lipoic acid
containing lipoic
Prior art date
Application number
MX2009011165A
Other languages
English (en)
Spanish (es)
Inventor
Robert G I Shorr
Rajinder Bhasin
Robert J Rodriguez
Original Assignee
Cornerstone Pharmaceuticals In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornerstone Pharmaceuticals In filed Critical Cornerstone Pharmaceuticals In
Publication of MX2009011165A publication Critical patent/MX2009011165A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicinal Preparation (AREA)
MX2009011165A 2007-04-18 2008-04-17 Formulaciones farmaceuticas que contienen derivados del acido lipoico. MX2009011165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91260507P 2007-04-18 2007-04-18
PCT/US2008/060650 WO2008131114A2 (en) 2007-04-18 2008-04-17 Pharmaceutical formulations containing lipoic acid derivatives

Publications (1)

Publication Number Publication Date
MX2009011165A true MX2009011165A (es) 2009-12-09

Family

ID=39872894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011165A MX2009011165A (es) 2007-04-18 2008-04-17 Formulaciones farmaceuticas que contienen derivados del acido lipoico.

Country Status (19)

Country Link
US (4) US20080262077A1 (enExample)
EP (1) EP2144609B1 (enExample)
JP (1) JP5480804B2 (enExample)
KR (1) KR101539785B1 (enExample)
CN (1) CN101820875B (enExample)
AR (1) AR067309A1 (enExample)
AU (1) AU2008242827B2 (enExample)
BR (1) BRPI0810439B1 (enExample)
CA (1) CA2684479C (enExample)
CL (1) CL2008001124A1 (enExample)
ES (1) ES2528414T3 (enExample)
IL (1) IL201581A (enExample)
MX (1) MX2009011165A (enExample)
NZ (1) NZ580973A (enExample)
PL (1) PL2144609T3 (enExample)
PT (1) PT2144609E (enExample)
SA (1) SA08290240B1 (enExample)
TW (1) TWI459944B (enExample)
WO (1) WO2008131114A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5412423B2 (ja) 2007-04-18 2014-02-12 コーナーストーン ファーマシューティカルズ，インコーポレーテッド リポ酸誘導体
CN101820875B (zh) 2007-04-18 2014-07-23 基石医药公司 含有硫辛酸衍生物的药物制剂
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
BRPI0821176A2 (pt) * 2008-03-04 2015-10-06 Robert Rodriguez modulador do estado de fosforilação de pelo menos um complexo de enzimas, método para modular o complexo de pdh em um paciente que apresenta uma doença, condição, ou síndrome e método pra diagnosticar e predizer benefício em um paciente que apresenta sintomas de uma doença, condição, ou síndrome causada por uma alteração da estrutura e/ou da atividade do complexo de pdh
MX2010010867A (es) * 2008-04-04 2011-05-25 Robert Shorr Composicion farmaceutica.
KR20110103987A (ko) * 2008-12-01 2011-09-21 인베이스크 테라퓨틱, 인크. 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
EP3403647A1 (en) 2009-12-01 2018-11-21 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2011143590A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CN102657606B (zh) * 2012-05-25 2014-01-01 江苏神龙药业有限公司 一种供静脉给药用的硫辛酸注射液
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
HK1216619A1 (zh) * 2012-12-19 2016-11-25 Robert Shorr 藥物化合物
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
CN103360437B (zh) * 2013-04-27 2015-10-21 江苏教育学院 一种硫辛酸糖类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN103497344B (zh) * 2013-09-25 2015-09-23 深圳先进技术研究院 用于负载贵金属颗粒的纳米凝胶及其制备方法与应用
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
MX373952B (es) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Métodos de purificación de arn mensajero.
WO2015195070A1 (en) * 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
WO2015195071A1 (en) * 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
TW202114651A (zh) * 2019-08-16 2021-04-16 美商拉斐爾製藥公司 用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物
WO2021174135A1 (en) * 2020-02-28 2021-09-02 University Of Florida Research Foundation, Incorporated Compounds that modulate anti-tumor immunity and methods of doing the same
CA3197188A1 (en) * 2020-11-03 2022-05-12 Sanjeev LUTHER Therapeutic methods and compositions for treating biliary tract cancer using devimistat
CN119770650A (zh) * 2025-01-09 2025-04-08 华中科技大学 一种硫辛酸-胆碱离子液体溶液及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805251A (en) * 1953-07-22 1957-09-03 Ethyl Corp Preparation of aryloxyaliphatic acids and salts thereof
GB758897A (en) 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US2809978A (en) * 1953-12-04 1957-10-15 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US3002011A (en) * 1953-12-04 1961-09-26 Merck & Co Inc Intermediates and processes for producing alpha-lipoic acid
US2980716A (en) * 1954-06-11 1961-04-18 Research Corp Method for preparing 6, 8-dihalooctanoic esters
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2852531A (en) * 1954-09-24 1958-09-16 Merck & Co Inc Tris-(2-tetrahydropyranyl) esters of 6, 8-bis (hydrocarbonmercapto)-4, 4-dicarboxy-5-ocaprylic acid and preparation thereof
US2875238A (en) * 1957-02-19 1959-02-24 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2875239A (en) * 1957-02-19 1959-02-24 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2985685A (en) * 1959-01-26 1961-05-23 American Cyanamid Co Alkanolamine aluminates as catalysts for ester redistribution
US3453312A (en) * 1966-04-27 1969-07-01 Merck & Co Inc (beta - (substituted-thio) - acylphenoxy)-alkanoic acids and (beta-(substitutedthio) acylphenylmercapto) alkanoic acids and derivatives thereof
US3345368A (en) * 1967-02-15 1967-10-03 American Cyanamid Co Substituted 7-acetylamino cephalosporanic acids
DE2422498A1 (de) * 1973-05-18 1974-12-05 Ciba Geigy Ag Neue thiaprostaglandine und verfahren zu ihrer herstellung
US3881017A (en) * 1973-05-18 1975-04-29 Ciba Geigy Corp 9-Thiaprostaglandin compositions
JPS5323539Y2 (enExample) * 1973-11-30 1978-06-17
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
US5344941A (en) * 1986-09-03 1994-09-06 Samour Carlos M Water soluble salts of thionaphthene-2-carboxylic acid
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6331559B1 (en) * 1998-10-26 2001-12-18 The Research Foundation Of State University Of New York At Stony Brook Lipoic acid derivatives and their use in treatment of disease
US7320797B2 (en) * 2003-08-29 2008-01-22 Bioderm Research Antiaging cosmetic delivery systems
JP2007077066A (ja) * 2005-09-14 2007-03-29 Shiseido Co Ltd 不全角化抑制剤、毛穴縮小剤
US20090036356A1 (en) * 2006-03-06 2009-02-05 Avestha Gengraine Technologies Pvt. Ltd. Octanoic acid derivatives as dipeptidyl peptidase inhibitors
JP5412423B2 (ja) * 2007-04-18 2014-02-12 コーナーストーン ファーマシューティカルズ，インコーポレーテッド リポ酸誘導体
CN101820875B (zh) 2007-04-18 2014-07-23 基石医药公司 含有硫辛酸衍生物的药物制剂
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives

Also Published As

Publication number Publication date
BRPI0810439A2 (pt) 2014-10-07
US9320726B2 (en) 2016-04-26
KR20100029744A (ko) 2010-03-17
NZ580973A (en) 2011-10-28
AU2008242827B2 (en) 2014-06-05
AU2008242827A1 (en) 2008-10-30
WO2008131114A2 (en) 2008-10-30
HK1140424A1 (en) 2010-10-15
PT2144609E (pt) 2015-02-06
US20120178812A1 (en) 2012-07-12
US20170056355A1 (en) 2017-03-02
EP2144609A2 (en) 2010-01-20
CL2008001124A1 (es) 2009-01-02
SA08290240B1 (ar) 2012-02-22
BRPI0810439B1 (pt) 2021-06-29
TW200901964A (en) 2009-01-16
AR067309A1 (es) 2009-10-07
CN101820875A (zh) 2010-09-01
CA2684479A1 (en) 2008-10-30
IL201581A0 (en) 2010-05-31
CN101820875B (zh) 2014-07-23
JP5480804B2 (ja) 2014-04-23
KR101539785B1 (ko) 2015-07-27
CA2684479C (en) 2017-11-14
ES2528414T3 (es) 2015-02-10
JP2010524963A (ja) 2010-07-22
EP2144609B1 (en) 2014-10-29
TWI459944B (zh) 2014-11-11
WO2008131114A3 (en) 2010-01-21
EP2144609A4 (en) 2010-06-16
US20150011633A1 (en) 2015-01-08
US8691873B2 (en) 2014-04-08
IL201581A (en) 2016-04-21
US20080262077A1 (en) 2008-10-23
PL2144609T3 (pl) 2015-04-30
US9872845B2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
MX2009011165A (es) Formulaciones farmaceuticas que contienen derivados del acido lipoico.
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
DK2442790T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
DK2254549T4 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser
SI2194969T1 (sl) Lipidne formulacije, ki vsebujejo kislino
ZA201001160B (en) Drug formulations having inert sealed cores
IL201611A0 (en) Lipoic acid derivatives
SI2966175T1 (sl) Farmacevtski sestavki vsebujoči korteksolon-17-alfa-propionat
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
HUE036876T2 (hu) 4,5-Epoximorfinán származékot tartalmazó stabil tabletta
ITFI20080016A1 (it) Formulazioni farmaceutiche orali contenenti gliclazide.
PL2004149T3 (pl) Preparaty farmaceutyczne zawierające leflunomid
PT2568970T (pt) Formulações farmacêuticas estáveis contendo um anti-histamínico
BRPI0811073A2 (pt) Formulações de amino ácido -n-halogenado contendo ácido alifático
EP2347662A4 (en) KIT OF PHARMACEUTICAL FORMULATIONS CHARACTERIZED BY THE PRESENCE OF MOLECULAR OXYGEN
HU0700755D0 (en) Pharmaceutical compositions containing capsaicionid
IL196773A0 (en) Stable solid elsamitrucin salts suitable for pharmaceutical formulations
HK1152253A (en) Stabilizing lipid compositions for oral pharmaceutical agents
GB0713093D0 (en) Pharmaceutical formulations
HK1143548A (en) Drug formulations having inert sealed cores
GB0810217D0 (en) Pharmaceutical formulations
GB0813031D0 (en) Pharmaceutical formulations
HK1131061A (en) Stable pharmaceutical drug aerosols
HK1143080A (en) High concentration local anesthetic formulations

Legal Events

Date Code Title Description
FG Grant or registration